BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28849946)

  • 21. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA; Lau YC; Lip GY
    Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
    Bash LD; Buono JL; Davies GM; Martin A; Fahrbach K; Phatak H; Avetisyan R; Mwamburi M
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):167-79. PubMed ID: 22418856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
    Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
    J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A; Niederdoeckl J; Skyllouriotis E; Schuetz N; Herkner H; Weiser C; Laggner AN; Domanovits H; Spiel AO
    Europace; 2017 Feb; 19(2):233-240. PubMed ID: 28175295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring.
    Manolis AS; Bethanis S; Metaxa S; Polytarchou K; Sakellaris N; Pyrros I
    Hellenic J Cardiol; 2019; 60(1):54-56. PubMed ID: 29454598
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
    Blomström-Lundqvist C; Blomström P
    Expert Opin Drug Saf; 2012 Jul; 11(4):671-9. PubMed ID: 22632377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide.
    Peters FP; Braat SH; Heymeriks J; Wellens HJ
    Neth J Med; 1998 Sep; 53(3):93-6. PubMed ID: 9803139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation.
    Limantoro I; De Vos CB; Delhaas T; Marcos E; Blaauw Y; Weijs B; Tieleman RG; Pisters R; Schotten U; Van Gelder IC; Crijns HJ
    Heart Rhythm; 2014 Mar; 11(3):478-84. PubMed ID: 24321238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation.
    Climent VE; Marin F; Mainar L; Gomez-Aldaravi R; Martinez JG; Chorro FJ; Roman P; Sogorb F
    Pacing Clin Electrophysiol; 2004 Mar; 27(3):368-72. PubMed ID: 15009866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.
    McIntyre WF; Healey JS; Bhatnagar AK; Wang P; Gordon JA; Baranchuk A; Deif B; Whitlock RP; Belley-Côté ÉP
    Europace; 2019 Aug; 21(8):1159-1166. PubMed ID: 31292622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
    J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study.
    Dominijanni G; Caballero-Bermejo AF; Martín Jiménez ML; Calpe Delgado P; Rodríguez-Miranda B; Ruiz-Antorán B
    Emergencias; 2024 Jun; 36(3):239-240. PubMed ID: 38819000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.